Compare TMP & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMP | ABCL |
|---|---|---|
| Founded | 1836 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 1996 | 2020 |
| Metric | TMP | ABCL |
|---|---|---|
| Price | $101.03 | $5.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $87.00 | $8.40 |
| AVG Volume (30 Days) | 84.5K | ★ 6.8M |
| Earning Date | 04-24-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 126.16 | 10.91 |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $75,742,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.94 | $21.85 |
| P/E Ratio | $50.91 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $61.87 | $2.75 |
| 52 Week High | $97.12 | $8.44 |
| Indicator | TMP | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 69.39 | 38.49 |
| Support Level | $81.87 | $5.23 |
| Resistance Level | N/A | $5.63 |
| Average True Range (ATR) | 2.16 | 0.54 |
| MACD | 0.15 | -0.25 |
| Stochastic Oscillator | 97.41 | 0.32 |
Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.